Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Characterisation of Citrullinated TFPI and Truncated TFPI Constructs By PAD4 in Model and Plasma Systems

M.G.L. Christella D. Thomassen, Dennis P.L. Suylen, Tilman M. Hackeng, PhD, Rory R. Koenen, PhD

Blood (2019) 134 (Supplement_1): 2390.

https://doi.org/10.1182/blood-2019-131190

Published: 2019

Journal Articles

To Test or Not to Test? Quantifying and Reducing Inappropriate Hypercoagulable Workups in the Inpatient Setting

Mariola Vazquez-Martinez, MD, Erika Correa, MD MS, Shaun Hanson, MD, Kathleen Degen, MD, Kevin D'Mello, MD, Kristine Ward, MD, Michael Styler, MD

Blood (2018) 132 (Supplement 1): 5819.

https://doi.org/10.1182/blood-2018-99-117183

Published: 2018

Journal Articles

Yearly Percent Incidence of Suspected Novel Oral Anticoagulant Interference on Thrombophilia Testing: A Nine Year Experience at a Reference Coagulation Laboratory

Edward C.C. Wong, MD MA, Laura A. Worfolk, PhD, Jeffrey S. Dlott, MD

Blood (2018) 132 (Supplement 1): 4819.

https://doi.org/10.1182/blood-2018-99-112972

Published: 2018

Journal Articles

Using Electronic Best Practice Alerts to Improve Thrombophilia Testing Based on ASH Choosing Wisely Guidelines

Tomi Jun, MD, Henry Kwang, MD, Eric Mou, MD, Caroline Berube, MD, Neil Shah, MD, Rajani Kaimal, MS, Jason Bentley, PhD, Neera Ahuja, MD, Lisa Shieh, MD, Jason Hom, MD

Blood (2017) 130 (Supplement 1): 3355.

https://doi.org/10.1182/blood.V130.Suppl_1.3355.3355

Published: 2017

Journal Articles

Centralized Laboratory Testing for Inhibitors in the U.S. Hemophilia Treatment Centers Network: Testing Protocol and Results on 10,178 Specimens

Connie H Miller, PhD, Dorothy Ellingsen, Jennifer Driggers, Brian Boylan, Amanda B. Payne, MPH, Fiona Bethea, MPH, Vanessa R Byams, MPH, J. Michael Soucie, PhD, Christopher J. Bean, PhD

Blood (2017) 130 (Supplement 1): 3692.

https://doi.org/10.1182/blood.V130.Suppl_1.3692.3692

Published: 2017

Journal Articles

Dilute Russell Viper Venom Time Interpretation and Clinical Correlation: A Two-Year Retrospective Institutional Review

Cyril Jacquot, MDPhD, Geoffrey D. Wool, MD PhD, Scott C. Kogan, MD

Blood (2016) 128 (22): 2609.

https://doi.org/10.1182/blood.V128.22.2609.2609

Published: 2016

Journal Articles

Rapaport SI, Aas K, Owren PA. The clotting action of Russell viper venom. Blood . 1954;9(12): 1185-1194 .

Blood (2016) 127 (9): 1077.

https://doi.org/10.1182/blood-2016-01-692822

Published: 2016

Journal Articles

TFPI Expresses Anticoagulant Activity Independent Of TF-FVIIa

Stella Thomassen, PhD, Alexandra Heinzmann, PhD, Linda Herfs, Jan Rosing, PhD, Tilman M. Hackeng, PhD, Rudolf Hartmann, PhD, Friedrich Scheiflinger, PhD, Michael Dockal, PhD

Blood (2013) 122 (21): 3563.

https://doi.org/10.1182/blood.V122.21.3563.3563

Published: 2013

Journal Articles

Prothrombinase Induced Clotting Time (PICT) and Commercially Available Diluted Russell's Viper Venom Times For The Monitoring Of New Oral Anticoagulants

Debra Hoppensteadt, Ph.D., Jeanine M. Walenga, PhD, Josephine Cunanan, Omer Iqbal, MD, Jawed Fareed, Ph.D.

Blood (2013) 122 (21): 3642.

https://doi.org/10.1182/blood.V122.21.3642.3642

Published: 2013

Journal Articles

Novel Point-Of-Use FXa Assay For Monitoring Anticoagulant Therapy By Oral Factor Xa Inhibitors and Heparin

Nina Lukinova, Ph.D., Mano Venkatesan, Jill White

Blood (2013) 122 (21): 4816.

https://doi.org/10.1182/blood.V122.21.4816.4816

Published: 2013

Journal Articles

Does Protease Domain of Human Factor IXa Contain a Sodium Site? Evidence From the 1.64 Å Resolution Crystal Structure

Kanagasabai Vadivel, Amy E Schmidt, S. Paul Bajaj

Blood (2011) 118 (21): 2246.

https://doi.org/10.1182/blood.V118.21.2246.2246

Published: 2011

Journal Articles

Impact of Factor × Mutations on the Activity of Edoxaban

Kengo Noguchi, Shin-ichi Takahashi, PhD, Hiroaki Ishihara, PhD, Yoshiyuki Morishima, PhD, Toshiro Shibano, PhD, Yasuo Ikeda, MD, PhD, Mitsuru Murata, MD, PhD

Blood (2010) 116 (21): 3321.

https://doi.org/10.1182/blood.V116.21.3321.3321

Published: 2010

Journal Articles

An Analysis of Cleavage of the Factor IX Activation Sites by Factor XIa

David Gailani, Stephen B. Smith, Sayeh Agah, S. Paul Bajaj

Blood (2008) 112 (11): 3088.

https://doi.org/10.1182/blood.V112.11.3088.3088

Published: 2008

Journal Articles

Plasma from Patients with a Lupus Anticoagulant Induce Tissue Factor Activity in Monocytes of Whole Blood-a Possible Risk Factor for Thrombosis

Dzung Le, MD, PhD, Diep Ho, Jan Ole Olsen, Bjarne Østerud

Blood (2008) 112 (11): 3830.

https://doi.org/10.1182/blood.V112.11.3830.3830

Published: 2008

Journal Articles

Partial Reversal of the Anticoagulant Effect of High-Dose Rivaroxaban - An Oral, Direct Factor Xa Inhibitor - by Recombinant Factor VIIa in Rats.

Hanna Tinel, PhD, Joachim Huetter, PhD, Elisabeth Perzborn, MD

Blood (2006) 108 (11): 915.

https://doi.org/10.1182/blood.V108.11.915.915

Published: 2006

Journal Articles

Evidence That the COOH-Terminal Region of Factor Va Heavy Chain Is Involved in the Regulation of Prothrombinase Activity.

Jamila Hirbawi, BS, Melissa A. Blum, BS, Michael A. Bukys, BS, Tivadar Orban, BS, Michael Kalafatis, PhD

Blood (2005) 106 (11): 1025.

https://doi.org/10.1182/blood.V106.11.1025.1025

Published: 2005

Journal Articles

Distinguishing Antiphospholipid Antibodies from an Acquired Factor Inhibitor: A Novel Laboratory Approach.

Kurt P. Leuenberger, MD, Spero Cataland, MD, Ming Jin, MD, PhD, Carol Orr, Guido Marcucci, MD, Eric H. Kraut, MD, Haifeng M. Wu, MD

Blood (2005) 106 (11): 2150.

https://doi.org/10.1182/blood.V106.11.2150.2150

Published: 2005

Journal Articles

Comparison of aPTT (Platelin LS®) and Dilute Russell’s Viper Venom (Viperquik LA Test®) for the Screening of Lupus Anticoagulant in Patients with Venous Thromboembolism.

Celso A. Roprigues, MD, Aline A. Martinez, MD, Vania M. Morelli, MD, Raniely C. Silveira, BSc, Maria Aparecida E. Noguti, BSc, Dayse M. Lourenco, MD

Blood (2005) 106 (11): 4122.

https://doi.org/10.1182/blood.V106.11.4122.4122

Published: 2005

Journal Articles

Allogeneic Non Myeloablative Blood Stem Cell Transplantation for NHL in a Patient with Systemic Lupus Erythematosus: Clinical Outcome and Long Term Follow-Up.

M. B. Koh, ph.D, P. E. Patten, S. A. Schey, MD

Blood (2004) 104 (11): 5136.

https://doi.org/10.1182/blood.V104.11.5136.5136

Published: 2004

Journal Articles

Association of Protein Z Deficiency with Retinal Artery and Vein Occlusion.

Maya Koren-Michowitz, MD, Eva Eting, MD, Yulia Voltchek, MD, Naomi Rahimi-Levene, MD, Osnat Garach-Jehoshua, PhD, Abraham Kornberg, MD

Blood (2004) 104 (11): 3510.

https://doi.org/10.1182/blood.V104.11.3510.3510

Published: 2004

NARROW

Characterisation of Citrullinated TFPI and Truncated TFPI Constructs By PAD4 in Model and Plasma Systems

To Test or Not to Test? Quantifying and Reducing Inappropriate Hypercoagulable Workups in the Inpatient Setting

Yearly Percent Incidence of Suspected Novel Oral Anticoagulant Interference on Thrombophilia Testing: A Nine Year Experience at a Reference Coagulation Laboratory

Using Electronic Best Practice Alerts to Improve Thrombophilia Testing Based on ASH Choosing Wisely Guidelines

Centralized Laboratory Testing for Inhibitors in the U.S. Hemophilia Treatment Centers Network: Testing Protocol and Results on 10,178 Specimens

Dilute Russell Viper Venom Time Interpretation and Clinical Correlation: A Two-Year Retrospective Institutional Review

Rapaport SI, Aas K, Owren PA. The clotting action of Russell viper venom. Blood . 1954;9(12): 1185-1194 .

TFPI Expresses Anticoagulant Activity Independent Of TF-FVIIa

Prothrombinase Induced Clotting Time (PICT) and Commercially Available Diluted Russell's Viper Venom Times For The Monitoring Of New Oral Anticoagulants

Novel Point-Of-Use FXa Assay For Monitoring Anticoagulant Therapy By Oral Factor Xa Inhibitors and Heparin

Does Protease Domain of Human Factor IXa Contain a Sodium Site? Evidence From the 1.64 Å Resolution Crystal Structure

Impact of Factor × Mutations on the Activity of Edoxaban

An Analysis of Cleavage of the Factor IX Activation Sites by Factor XIa

Plasma from Patients with a Lupus Anticoagulant Induce Tissue Factor Activity in Monocytes of Whole Blood-a Possible Risk Factor for Thrombosis

Partial Reversal of the Anticoagulant Effect of High-Dose Rivaroxaban - An Oral, Direct Factor Xa Inhibitor - by Recombinant Factor VIIa in Rats.

Evidence That the COOH-Terminal Region of Factor Va Heavy Chain Is Involved in the Regulation of Prothrombinase Activity.

Distinguishing Antiphospholipid Antibodies from an Acquired Factor Inhibitor: A Novel Laboratory Approach.

Comparison of aPTT (Platelin LS®) and Dilute Russell’s Viper Venom (Viperquik LA Test®) for the Screening of Lupus Anticoagulant in Patients with Venous Thromboembolism.

Allogeneic Non Myeloablative Blood Stem Cell Transplantation for NHL in a Patient with Systemic Lupus Erythematosus: Clinical Outcome and Long Term Follow-Up.

Association of Protein Z Deficiency with Retinal Artery and Vein Occlusion.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only